OncoMatch/Clinical Trials/NCT07452198
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Is NCT07452198 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including GR1803 and Daratumumab for multiple myeloma.
Treatment: GR1803 · Daratumumab · Pomalidomide · Dexamethasone — The purpose of this study is to compare the efficacy of GR1803 Injection with daratumumab in combination with pomalidomide and dexamethasone (DPd).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
Received 1 to 3 prior line(s) of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide
Must have received: immunomodulatory drug (lenalidomide)
Received 1 to 3 prior line(s) of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide
Cannot have received: B cell maturation antigen (BCMA)-directed therapy
Received any prior B cell maturation antigen (BCMA)-directed therapy.
Cannot have received: anti-CD38 therapy
Exception: disease that is considered refractory or intolerant to an anti-cluster of differentiation 38 (CD38) targeted therapy
Has disease that is considered refractory or intolerant to an anti-cluster of differentiation 38 (CD38) targeted therapy
Cannot have received: pomalidomide (pomalidomide)
Exception: disease that is considered refractory or intolerant to Pomalidomide
Has disease that is considered refractory or intolerant to ... Pomalidomide
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify